David A Hornback MD

Radiation Oncology•South Bend, IN

Medical Director

Join to View Full Profile

621 Memorial DrSte 100South Bend, IN 46601
Phone+1 574-647-1100
Fax+1 574-647-3148

Education & Training

Indiana University School of MedicineResidency, Radiation Oncology, 1989 - 1992
Ascension St Vincent Hospital IndianapolisInternship, Transitional Year, 1988 - 1989
Indiana University School of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 2012 - Present
IN State Medical License 1989 - 2025
MI State Medical License 1990 - 2019
American Board of Radiology Radiation Oncology

Clinical Trials

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Start of enrollment: 2011 May 24
ACTIVE_NOT_RECRUITING
PHASE3
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2012 Dec 20
Completed
Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer Start of enrollment: 2013 Mar 22
RECRUITING
PHASE2, PHASE3
Join now to see all

Publications & Presentations

PubMed

95 citations
Phase II Randomized Trial of Two Nonoperative Regimens of Induction Chemotherapy Followed by Chemoradiation in Patients With Localized Carcinoma of the Esophagus: RTOG...
Jaffer A. Ajani, Kathryn Winter, Ritsuko Komaki, D. P. Kelsen, Bruce D. Minsky
Journal of Clinical Oncology. 2008-10-01
10 citations
Dual 24-hour feeding response to 2DG in rats: Daytime increase and nighttime decrease
Carl I. Thompson, Robert L. Fleming, Kenneth A. Franken, David A. Hornback, Steven P. Boha
Physiology & Behavior. 1989-01-01

David A Hornback MD

Dr. Hornback is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.